[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100651173":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":30,"locations":38,"responsibleParty":52,"collaborators":34,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":34,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":34,"overallStatus":75,"whyStopped":34,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"University of Wisconsin, Madison","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Healthy adults on Tirzepatide","EXPERIMENTAL","Participants will complete a screening and enrollment visit, one study visit, and a follow-up correspondence over the course of approximately 4 weeks.",[13],"Drug: Acute Ethanol Dose",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Acute Ethanol Dose","Time 0, participants will self-administer an oral ethanol beverage (vodka and sugar-free cherry Kool aid) calculated to reach a peak Breath Alcohol Concentration (BrAC) of 0.08 g\u002FdL using the Widmark formula. A total time of 30 minutes will be given for completion of beverage consumption. This will be followed by a breakfast.",[9],[21],"vodka",[23,27],{"name":24,"affiliation":25,"role":26},"Heather Barkholtz, PhD","UW School of Pharmacy","PRINCIPAL_INVESTIGATOR",{"name":28,"affiliation":29,"role":26},"Michael Chen, MD","UW School of Medicine and Public Health",[31,36],{"name":24,"role":32,"phone":33,"phoneExt":34,"email":35},"CONTACT","608-890-1967",null,"hbarkholtz@wisc.edu",{"name":28,"role":32,"phone":34,"phoneExt":34,"email":37},"michael.chen@fammed.wisc.edu",[39],{"facility":40,"status":34,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":34},"University of Wisconsin","Madison","Wisconsin","53792","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-89.40123,43.07305,{"lat":50,"lon":49},{"type":53,"investigatorFullName":34,"investigatorTitle":34,"investigatorAffiliation":34,"oldNameTitle":34,"oldOrganization":34},"SPONSOR","100651173","phase-1-impact-of-glp-1-receptor-agonist-therapy-on-alcohol-pharmacokinetics-100651173",false,"NCT07758231","Impact of GLP-1 Receptor Agonist Therapy on Alcohol Pharmacokinetics","TAP","Inclusion Criteria:\n\n* At least 21 years of age, no older than 55 years of age\n* BMI 30-45 kg\u002Fm2\n* Taking stable dose of prescribed, branded tirzepatide for at least 28 days\n* Self-reported regular alcohol consumption\n* Good mental health as determined by self-reported responses to the Psychopathology Screener and review by Study Physician as necessary\n* Absence of any major medical, cardiovascular, endocrine, and neurological condition as determined by self-reported responses to the Medical History Screener\n* In possession of a valid drivers' license with at least two years of driving experience\n* English-speaking (able to provide consent and complete questionnaires)\n* Written Informed Consent\n\nExclusion Criteria:\n\n* AUDIT score of \\>8 requires Study Physician review\n* Use of compounded GLP-1 RA\n* History of or current substance use disorder as determined by self-reported responses to the Internalizing, Externalizing, and Substance Use Disorder Screener, Drug Use Disorders Identification Test, Alcohol Use Disorder Identification Test\n* Pregnancy or lactation (pregnancy test, if needed)\n* Use of medications that may impact cognitive ability or potentiate alcohol (e.g., mood stabilizers, sedatives)\n* Use of medications that are known to significantly delay gastric emptying as determined by Study Physician\n* History of pancreatitis, severe gastroparesis, or personal or family history of medullary thyroid or multiple endocrine neoplasia syndrome type 2",true,"ALL","21 Years","55 Years",{"count":66,"type":67},5,"ESTIMATED","INTERVENTIONAL",[70],"PHASE1","This study is to learn how the weight loss drug tirzepatide (Zepbound) changes the way a body handles alcohol. 5 participants aged 21-55 who take Zepbound will be enrolled and can expect to be on study for up to 4 weeks.",[73,74],"GLP-1","Alcohol","NOT_YET_RECRUITING","2026-08-05",{"date":78,"type":79},"2026-08-11","ACTUAL",{"date":81,"type":67},"2026-10",{"date":83,"type":67},"2027-03",{"name":5,"class":6},1]